Moreover, SIRT1 facilitates chemoresistance of pancreatic cancer cells by regulating adaptive responses to chemotherapy-induced stress, and combination therapy with SIRT1 inhibitor and gemcitabine was shown to have enhanced efficacy for pancreatic carcinoma [8, 9]. This evidence concerns the gene SIRT1 and pancreatic neoplasm.